Although drug-eluting stents are still the default interventional treatment of coronary artery
disease, drug-coated balloons (DCBs) represent a novel alternative therapeutic strategy in …

Cardiovascular diseases (CVDs) remain a leading cause of morbidity and mortality globally.
Despite significant advancements in the development of pharmacological therapies, the …

Objectives The aim of this randomized controlled trial was to investigate a novel sirolimus-
coated balloon (SCB) compared with the best investigated paclitaxel-coated balloon (PCB) …

Objectives The aim of this randomized controlled trial was to investigate a novel sirolimus-
coated balloon (SCB) compared with the best investigated paclitaxel-coated balloon (PCB) …

Drug-coated balloon treatment in coronary artery disease: Recommendations from an Asia-Pacific
Consensus Group Page 1 Address for correspondence: Eun-Seok Shin, MD, PhD, Division of …

Objectives: The aim of this first-in-human study was to assess the safety and effectiveness of
the Virtue sirolimus-eluting balloon in a cohort of patients with in-stent restenosis (ISR) …

Background: Paclitaxel-coated balloons (PCBs) are a preferred treatment option for
coronary in-stent restenosis. To date, data from randomized trials of alternative drug …

Background Although use of sirolimus‐based analogs has shown superiority over paclitaxel
in drug‐eluting stents, the relative efficacy of these two agents released from drug‐coated …

Restenosis remains the main reason for treatment failure of arterial disease. Sirolimus (SIR)
as a potent anti-proliferative agent is believed to prevent the phenomenon. The application …

Drug delivery is central to modern cardiovascular care, where drug-eluting stents,
bioresorbable scaffolds, and drug-coated balloons all aim to restore perfusion while …